2026 Interim report
Filed with HKEX · Stock code 9606 · · 115 pages · English
Definitions and Glossary of Technical Terms Company Profile Corporate Information Chairman Statement Financial Highlights Business Highlights Management Discussion and Analysis Corporate Governance and Other Information Report on Review of Interim Financial Information Interim Condensed Consolidated Statement of Comprehensive Loss 69 Interim Condensed Consolidated Balance Sheet 70 Interim Condense
Duality Biotherapeutics, Inc. on 6ix
Earlier from Duality Biotherapeutics
- DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
- DualityBio (9606.HK) Announces 2025 Annual Results
- DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
- First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
- Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
Later from Duality Biotherapeutics
- Next Day Disclosure Return
- An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Inside information - update on the dynasty-BREAST02 global phase 3 clinical trial of trastuzumab pamirtecan
Follow Duality Biotherapeutics into a list and get an email when it puts out news.
Follow Duality Biotherapeutics